Vasopressin-receptor antagonists in heart failure

American Journal of Health-System Pharmacy

Volumn 65, Issue 9, 2008, Pages 807-817

  Schweiger, Teresa A ^a,b   Zdanowicz, Martin M ^a,b  

^a LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^b South University

Author keywords

Cardiac drugs; Conivaptan; Heart failure; Lixivaptan; Mechanism of action; Tolvaptan; Toxicity; Vasopressin antagonists

Indexed keywords

ARGIPRESSIN; ARGIPRESSIN RECEPTOR; CONIVAPTAN; FUROSEMIDE; LIXIVAPTAN; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST;

ARTERY CONSTRICTION; BLOOD PRESSURE; CONGESTIVE HEART FAILURE; DEHYDRATION; DIURESIS; DIZZINESS; DRUG MECHANISM; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MORTALITY; NAUSEA; PATHOPHYSIOLOGY; PLASMA OSMOLARITY; POLYURIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; THIRST; URINE VOLUME; VASOCONSTRICTION; VENOCONSTRICTION; XEROSTOMIA;

EID: 43449094344     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070132     Document Type: Review

References (55)